Effects of Dominant-Negative Truncation Mutant ΔNTCF4 on Biological Characteristics of Renal Cancer Cell Line GRC-I by Down-Regulation Wnt Signaling Pathway Target Genes

YE Xiong-jun,Lin Gui-ting,Chang Zhi-jie,ZHANG Zhi-wen,XIN Dian-qi,WANG Xiao-feng,GUO Ying-lu

DOI: https://doi.org/10.3760/j:issn:1000-6702.2006.12.003

2006-01-01

Abstract:Objective To investigate the effects of dominant-negative truncation mutantΔNTCF4, lacking the N-terminal form of TCF4 gene,on biological characteristics of renal cancer cell line GRC-I and explore the molecular mechanisms.Methods GRC-I cell was transfected with pCDNA3-ΔNTCF4 eukary- otie expression plasmid,pCDNA3 empty vector to construct the stable cell line GRC-I/ΔNTCF4 and GRC-I/ Mock respectively.The morphological changes of stable cells were observed and the cells growth curve was detected through light microscope.The cellular proliferation activities were determined using the MTT assay. The protein expression of Wnt pathway downstream target gene C-Myc and Cox-2 was evaluated by immuno- cytoehemieal method and Western Blot analysis.Results After the dominant-negativeΔNTCF4 gene was permanently expressed,the GRC-I/ΔNTCF4 stable cells morphologically showed that appearance changed from circular to long-spindle shape,growth rate decreased with less karyosehisis found,malignant pheno- types reversed to normal renal tubular cells.MTT assay revealed that the proliferation activities of GRC-1/ΔNTCF4 cells were inhibited by 11.2%-35.5% compared with GRC-I cells (P＜0.05),while the GRC- I/Mock cells have no difference with the control cells.Immunocytochemical analysis and Western Blot showed that the C-Myc and Cox-2 protein expression level of GRC-I/ΔANTCF4 cells were significantly sup- pressed in comparison with that of GRC-I/Mock and GRC-I cells.Conclusions The dominant-negative truncation mutantΔNTCF4 could partially inhibit the growth of renal cancer cells and down-regulate the pro- tein expression of Wnt pathway target gene C-Myc and Cox-2.These findings provide a experimental founda- tion for applying cell signal therapy to renal cell cancer by blocking the Wnt signaling pathway.